CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference in New York, NY.
Company management will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" on Thursday, October 9, 2025, at 8:00 AM ET. The company will also be available for one-on-one meetings with institutional investors during the conference.
CervoMed (NASDAQ: CRVO), una società in fase clinica che sviluppa trattamenti per disturbi neurologici legati all'invecchiamento, ha annunciato la propria partecipazione alla 4ª Annual ROTH Healthcare Opportunities Conference a New York, NY.
La direzione parteciperà a una tavola rotonda intitolata Piccole aziende che affrontano indicazioni di grande impatto giovedì 9 ottobre 2025 alle 8:00 AM ET. L'azienda sarà inoltre disponibile per incontri individuali one-to-one con investitori istituzionali durante la conferenza.
CervoMed (NASDAQ: CRVO), una empresa en fase clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, anunció su participación en la 4.ª Annual ROTH Healthcare Opportunities Conference en Nueva York, NY.
La dirección de la compañía participará en un panel titulado Las pequeñas empresas que abordan indicaciones de gran impacto el jueves 9 de octubre de 2025 a las 8:00 a. m. ET. La empresa también estará disponible para reuniones individuales con inversores institucionales durante la conferencia.
CervoMed (NASDAQ: CRVO)는 노인성 신경질환 치료제를 개발 중인 임상 단계 회사로, 뉴욕시에서 열리는 제4회 로스헬스케어 기회 컨퍼런스에 참여한다고 발표했습니다.
회사 경영진은 대박 후보 지표를 다루는 소기업들라는 제목의 패널 토론에 2025년 10월 9일 목요일, 동부표준시 8:00 AM에 참가할 예정입니다. 또한 컨퍼런스 기간 동안 기관투자자들과의 일대일 미팅도 가능합니다.
CervoMed (NASDAQ: CRVO), société en phase clinique développant des traitements pour des troubles neurologiques liés à l’âge, a annoncé sa participation à la 4e Conférence annuelle ROTH Healthcare Opportunities à New York, NY.
La direction participera à une table ronde intitulée Petites entreprises abordant des indications de blockbuster le jeudi 9 octobre 2025 à 8 h 00 HNE. L’entreprise sera également disponible pour des entretiens individuels avec des investisseurs institutionnels pendant la conférence.
CervoMed (NASDAQ: CRVO), ein klinisch entwickelndes Unternehmen, das Behandlungen für altersbedingte neurologische Erkrankungen entwickelt, hat seine Teilnahme an der 4. jährlichen ROTH Healthcare Opportunities Conference in New York, NY, bekannt gegeben.
Die Geschäftsführung wird an einer Podiumsdiskussion mit dem Titel Kleine Unternehmen, die blockbuster-Indikationen angehen teilnehmen, am Donnerstag, dem 9. Oktober 2025 um 8:00 Uhr Eastern Time. Das Unternehmen steht während der Konferenz auch für One-on-One-Gespräche mit institutionellen Investoren zur Verfügung.
CervoMed (NASDAQ: CRVO)، شركة في مرحلة التطوير السريري تعمل على تطوير علاجات لاضطرابات عصبية مرتبطة بالعمر، أعلنت عن مشاركتها في مؤتمر ROTH Healthcare Opportunities الرابع في نيويورك، نيويورك.
ستشارك إدارة الشركة في جلسة نقاش بعنوان شركات صغيرة تعالج مؤشرات بارزة يوم الخميس 9 أكتوبر 2025 الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة. كما ستكون الشركة متاحة لعقد اجتماعات ثنائية مع مستثمرين مؤسسيين خلال المؤتمر.
CervoMed (NASDAQ: CRVO)，一家处于临床阶段、开发针对与年龄相关神经疾病的治疗方案的公司，宣布将参加在纽约举行的第四届 ROTH Healthcare Opportunities Conference。
公司管理层将出席题为 小型公司应对 blockbuster 指标 的小组讨论，时间为 美国东部时间 2025 年 10 月 9 日星期四 8:00。公司也将在会议期间与机构投资者进行一对一会谈。
- None.
- None.
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025.
Panel Details
Title: “Small Firms Tackling Blockbuster Indications”
Date: Thursday, October 9, 2025
Time: 8:00 AM ET
To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (CRVO) presenting at the ROTH Healthcare Conference 2025?
What is the focus of CervoMed's panel at the ROTH Healthcare Conference?
How can investors meet with CervoMed management at the ROTH Conference?
What type of company is CervoMed (CRVO)?
